Market Exclusive

Analyst Downgrades – Esperion Therapeutics (NASDAQ:ESPR) Stock Gets Downgraded By Citigroup from Buy to Neutral

Analyst Ratings For Esperion Therapeutics (NASDAQ:ESPR)

Today, Esperion Therapeutics (NASDAQ:ESPR) stock was downgraded by Citigroup from Buy to Neutral with a price target of $96.00.

Some recent analyst ratings include

Recent Insider Trading Activity For Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR) has insider ownership of 32.50% and institutional ownership of 92.30%.

Recent Trading Activity for Esperion Therapeutics (NASDAQ:ESPR)
Shares of Esperion Therapeutics closed the previous trading session at 77.23 up +0.03 0.04% with 85006 shares trading hands.

Exit mobile version